**Abstract**

*New Insights into Systemic Sclerosis*

2011;**24**(5):421-430

2001;**20**(3):205-210

[137] Lloyd DA, Vega R, Bassett P, Forbes A, Gabe SM. Survival and dependence on home parenteral nutrition: Experience over a 25-year period in a UK referral centre. Alimentary Pharmacology & Therapeutics. 2006;**24**(8):1231-1240

[138] Buchman AL, Iyer K, Fryer J. Parenteral nutrition-associated liver disease and the role for isolated intestine and intestine/liver transplantation. Hepatology. 2006;**43**(1):9-19

[139] Pironi L, Labate AM, Pertkiewicz M, Przedlacki J, Tjellesen L, Staun M, et al. Prevalence of bone disease in patients on home parenteral nutrition. Clinical Nutrition. 2002;**21**(4):289-296

[140] Puiggros C, Cuerda C, Virgili N, Chicharro ML, Martinez C, Garde C, et al. Catheter occlusion and venous thrombosis prevention and incidence in adult home parenteral nutrition (HPN) programme patients. Nutrición Hospitalaria. 2012;**27**(1):256-261

[141] Howard L. Home parenteral nutrition: Survival, cost, and quality of

life. Gastroenterology. 2006;**130**

[142] Ng SC, Clements PJ, Berquist WE, Furst DE, Paulus HE. Home central venous hyperalimentation in fifteen patients with severe scleroderma bowel

(2 Suppl 1):S52-S59

[135] Keld R, Kinsey L, Athwal V, Lal S. Pathogenesis, investigation and dietary and medical management of gastroparesis. Journal of Human Nutrition and Dietetics.

[136] Van Gossum A, Vahedi K, Abdel M, Staun M, Pertkiewicz M, Shaffer J, et al. Clinical, social and rehabilitation status of long-term home parenteral nutrition patients: Results of a European multicentre survey. Clinical Nutrition.

disease. Arthritis and Rheumatism.

[144] Brown M, Teubner A, Shaffer J, Herrick AL. Home parenteral nutrition—An effective and safe longterm therapy for systemic sclerosisrelated intestinal failure. Rheumatology

(Oxford). 2008;**47**(2):176-179

[145] Poelman CL, Hummers LK, Wigley FM, Anderson C, Boin F, Shah AA. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. The Journal of Rheumatology.

[146] Raja J, Nihtyanova SI, Murray CD, Denton CP, Ong VH. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford). 2016;**55**(1):115-119

[147] Clark KE, Etomi O, Denton CP, Ong VH, Murray CD. Intravenous immunoglobulin therapy for severe gastrointestinal involvement in systemic sclerosis. Clinical and Experimental Rheumatology. 2015;**33**(4 Suppl 91):

[148] Ciechomska M, van Laar J,

O'Reilly S. Current frontiers in systemic sclerosis pathogenesis. Experimental Dermatology. 2015;**24**(6):401-406

[143] Grabowski G, Grant JP. Nutritional support in patients with systemic scleroderma. JPEN Journal of Parenteral and Enteral Nutrition.

1989;**32**(2):212-216

1989;**13**(2):147-151

2015;**42**(2):236-242

S168-S170

**86**

Many clinical conditions are presenting with sclerosis of the skin and with tissue fibrosis. These conditions may be confused with systemic sclerosis (SSc, scleroderma). These diseases and disabilities are generally referred to as systemic sclerosis mimics or scleroderma-like syndromes. These disorders have very different etiologies and often an unclear pathogenetic mechanism. Distinct clinical characteristics, skin histology, and disease associations may allow distinguishing these conditions from systemic sclerosis and from each other. A histopathological examination with clinicopathological correlation for diagnosis is important to spare the patients from ineffective treatments and inadequate management. In this chapter, we discussed localized scleroderma, lichen sclerosus, nephrogenic systemic fibrosis, eosinophilic fasciitis, scleromyxedema, and scleredema. These are often detected in the primary care setting and referred to rheumatologists for further evaluation. Rheumatologists, or preferably in collaboration with a dermatologist, must be able to promptly recognize them to provide valuable prognostic information and appropriate treatment options for affected patients.

**Keywords:** localized scleroderma, lichen sclerosus, eosinophilic fasciitis, nephrogenic systemic fibrosis, scleromyxedema, scleredema
